Details

Autor(en) / Beteiligte

• Parsons, Ronald F.
• Zahid, Arslan
• Bumb, Shalini
• Decker, Hannah
• Sullivan, Harold C.
• Eun‐Hyung Lee, Frances
• Badell, Idelberto Raul
• Ford, Mandy L.
• Larsen, Christian P.
• Pearson, Thomas C.
• Jackson, Annette M.
• Chen, Dong‐Feng
• Levine, Matthew
• Kamoun, Malek
• Bray, Robert A.
• Gebel, Howard M.

Titel

The impact of belatacept on third‐party HLA alloantibodies in highly sensitized kidney transplant recipients

Ist Teil von

• American journal of transplantation, 2020-02, Vol.20 (2), p.573-581

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Recent evidence suggests that belatacept reduces the durability of preexisting antibodies to class I and class II human leukocyte antigens (HLAs). In this case series of 163 highly sensitized kidney transplant candidates whose calculated panel‐reactive antibody (cPRA) activity was ≥98% to 100%, the impact of belatacept on preexisting HLA antibodies was assessed. Of the 163 candidates, 72 underwent transplantation between December 4, 2014 and April 15, 2017; 60 of these transplanted patients remained on belatacept consecutively for at least 6 months. We observed a decrease in the breadth and/or strength of HLA class I antibodies as assessed by FlowPRA in belatacept‐treated patients compared to controls who did not receive belatacept. Specifically, significant HLA antibody reduction was evident for class I (P < .0009). Posttransplant belatacept‐treated patients also had a clinically significant reduction in their cPRA compared to controls (P < .01). Collectively, these findings suggest belatacept can reduce HLA class I antibodies in a significant proportion of highly sensitized recipients and could be an option to improve pretransplant compatibility with organ donors. This study suggests that belatacept reduces third‐party HLA class I antibodies in a significant proportion of highly sensitized kidney transplant recipients and may be another pretransplant option for patient desensitization.